What HemCon Medical Technologies does

HemCon Medical Technologies, operating as a product line under Tricol Biomedical, is a privately held medical device company headquartered in Portland, Oregon. Founded in 2001, the company develops and commercializes hemostatic wound-care products built on its proprietary Chito+ chitosan technology platform. Chito+ leverages a strong polycationic (positive) charge from chitosan (derived from crustacean shells) that binds with negatively charged biopolymers, tissues, and cells to enable rapid hemostasis and support the body's natural coagulation pathway. The technology was originally developed through a 2001 co-development partnership with the U.S. Army to produce hemostatic dressings for traumatic battlefield injuries.

The company's product portfolio is organized into three segments. (1) Trauma Management includes HemCon PRO hemostatic dressings for battlefield, pre-hospital, and emergency use. (2) Procedural Care offers non-invasive hemostasis solutions for medical procedures in acute and non-acute care settings, positioned as cost-effective alternatives to mechanical wound-closure devices. (3) Consumer Self-Care includes OneStop Bandage — designed to control bleeding rapidly even for patients on blood thinners, with bacterial barrier protection — and ChitoGauze for minor wounds. Trademarks (HemCon, Chito+, HemCon PRO, OneStop, ChitoGauze) are registered, and the Chito+ chemistry is the unifying technology platform across all products.

The business model is hardware sales of medical devices through a combination of direct enterprise field sales to medical facilities, authorized U.S. and international distribution networks, and OEM/co-development partnerships with other medical device companies that embed Chito+ into their own product lines. Pricing is not publicly disclosed; the company uses a consultative sample-and-evaluation sales motion with medical institutions. The customer base spans the U.S. Army / military, medical professionals in hospitals and clinics, and general consumers purchasing over-the-counter wound care. The company has 51–100 employees and has raised at least $12 million in disclosed funding (2007 round led by Camden Partners and Torch Hill Investment Partners); revenue is not publicly disclosed. Leadership includes CEO Michael Wax and CSO Simon McCarthy.

Name

HemCon Medical Technologies

Legal name

Tricol Biomedical

Website

https://hemcon.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

HemCon Medical Technologies (Tricol Biomedical) is a Portland, Oregon-based medical device company that develops hemostatic wound-care products built on proprietary Chito+ chitosan technology, serving military, medical-professional, and consumer markets across trauma, procedural, and self-care segments.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin) (HLAIAHAG)

Keywords

• Hemostatic dressings
• Chitosan wound care
• Trauma management devices
• Hemostasis medical devices
• Wound closure products

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Product Sales: Tricol Biomedical generates revenue through the sale of hemostatic medical devices and wound care products. Products are sold through direct sales channels and distribution partners to healthcare facilities, medical professionals, and consumers. The company offers products across three segments: Trauma Management (professional), Procedural Care (medical settings), and Consumer Care (direct to consumer).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

HemCon Medical Technologies manufactures and sells chitosan-based hemostatic dressings, bandages, and gauze products used to control bleeding rapidly in traumatic, procedural, and consumer wound-care settings. Products are built on the proprietary Chito+™ chitosan platform and are sold across three segments: Trauma Management (HemCon PRO hemostatic dressings for battlefield, pre-hospital, and emergency use), Procedural Care (non-invasive hemostatic solutions for medical procedures), and Consumer Care (OneStop™ Bandage and ChitoGauze® for home first-aid).

Product overview

HemCon Medical Technologies, now part of Tricol Biomedical, offers a portfolio of hemostatic medical devices built on its proprietary Chito+™ chitosan technology platform. The product line spans three categories: (1) Trauma Management—hemostatic dressings originally developed with the U.S. Army in 2001 for battlefield and pre-hospital use; (2) Procedural Care—non-invasive solutions for controlling bleeding during medical procedures in acute and non-acute care settings; and (3) Consumer Care—consumer-accessible versions including the OneStop™ Bandage and ChitoGauze® for home first-aid use. All products leverage the same core Chito+™ technology, which uses a positive charge mechanism to bind with negatively charged biological tissues and cells, enabling rapid hemostasis through the body's natural coagulation pathway.

Differentiator

Problem solved

Functional benefit

Brands

• Chito+: Proprietary chitosan technology used in HemCon PRO hemostatic products, featuring strong polycationic (positive) charge that promotes binding with biopolymers, tissues, and cells
• HemCon PRO
• OneStop
• ChitoGauze

Products and services

• HemCon PRO Hemostatic Dressings Hemostatic dressings using a strong polycationic (positive) charge from proprietary chitosan to bind with tissues and cells possessing negative charge, enabling rapid hemostasis and supporting the body's natural coagulation pathway. Designed for battlefield, pre-hospital, emergency, and trauma use.
• Procedural Care Hemostatic Products Non-invasive hemostatic solutions for quickly and safely controlling bleeding in medical procedures in both acute and non-acute care settings. Cost-effective compared to mechanical wound-closure devices and based on the proprietary Chito+ chitosan technology.
• OneStop Bandage Battlefield-proven consumer bandage that controls bleeding rapidly, even for patients on blood thinners. Also provides a barrier to bacterial penetration. Designed for home first-aid use.
• ChitoGauze Hemostatic gauze product based on proprietary chitosan technology that controls bleeding from minor wounds. Targeted at consumers for home wound care use.

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• U.S. ArmycoreStrategic or Co-development Partner · 1 January 2001In 2001, HemCon partnered with the U.S. Army to design a hemostatic dressing that would save the lives of soldiers who suffered traumatic injuries. This partnership led to the development of the proprietary Chito+ chitosan technology that forms the foundation of HemCon's product line.
• Medical Device CompaniescoreStrategic or Co-development PartnerTricol partners with medical device companies in providing safe, effective hemostasis solutions for their medical interventions. Using Tricol's proprietary chitosan Chito+, partners are positioned at a higher competitive level than their competitors. Co-development opportunities are available through the Partners section of the company website.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Z-Medica (Teleflex): Z-Medica, acquired by Teleflex, manufactures QuikClot hemostatic gauze and dressings—the most direct competitor to HemCon's Chito+ products in the battlefield and trauma hemostasis space. Both companies target military, EMS, and hospital channels with rapid-acting hemostatic dressings.
• MedTrade Products: MedTrade Products manufactures Celox hemostatic gauze, also based on chitosan chemistry, making it a near-identical technology peer to HemCon's Chito+ line. Both compete directly in military procurement, pre-hospital trauma, and civilian first-aid channels.
• Integra LifeSciences: Integra LifeSciences manufactures a portfolio of wound care and surgical hemostasis products including collagen- and gelatin-based dressings. It serves the same trauma, surgical, and advanced wound care customer base as HemCon across hospitals and ambulatory settings.
• CryoLife: CryoLife (now Artivion) manufactures surgical sealants and hemostatic agents used in cardiac and vascular surgery. It is a focused peer in the surgical hemostasis space where HemCon's procedural care products are positioned, though CryoLife's portfolio is protein-based rather than chitosan.

Broad incumbents

• Baxter International: Baxter markets Floseal and Tisseel fibrin-based hemostatic agents used in surgical settings. While its hemostasis products are plasma/protein-derived rather than chitosan-based, Baxter is a dominant incumbent in the operating room hemostasis market that HemCon competes against for procedural care accounts.
• Ethicon (Johnson & Johnson): Ethicon, a J&J subsidiary, sells Surgicel oxidized regenerated cellulose hemostats and other surgical hemostasis products. As one of the largest surgical device companies globally, Ethicon represents a deep-pocketed incumbent competing for the same procedural care accounts HemCon targets.
• Smith & Nephew: Smith & Nephew offers advanced wound management products (Allevyn, PICO) used in hospitals and home care. While not exclusively focused on hemostasis, it competes with HemCon's consumer and procedural wound care segments and is a much larger incumbent with global scale.
• 3M Health Care: 3M's Health Care division sells wound dressings, skin closures, and surgical products through its established hospital and retail channels. HemCon's ChitoGauze and OneStop Bandage compete against 3M's consumer and professional wound care offerings in the same end markets.
• Becton Dickinson (BD): BD offers surgical and infection prevention products, including hemostatic dressings and wound closure devices, through its large hospital sales force. As a major medical device incumbent, BD competes with HemCon in trauma management and procedural care accounts.

Emerging players

• Marine Polymer Technologies: Marine Polymer Technologies develops poly-N-acetyl glucosamine hemostatic products derived from marine algae—analogous to HemCon's chitosan approach. As a smaller specialty player, it competes in niche trauma and surgical hemostasis applications where HemCon's Chito+ technology is positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/HemConMedTech
• YouTubeyoutube.com/channel/UCJv2iM9neGPiWomtdQu_aww
• Facebookfacebook.com/TricolHemostasisBiomedical
• LinkedInlinkedin.com/company/hemcon-medical-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HemCon Medical Technologies